Panel of National Pathology Leaders (PNPL) Board members, Robert Tessier and Al Sirmon, recently presented at the 2024 Executive War College meeting in New Orleans. Their talk, "What’s New in Pathologist Productivity and Compensation Plus Boosting Profitability through Effective Negotiations with Hospitals and Payers," offered valuable perspectives on enhancing pathology practices' operational and financial aspects. Additionally, Dr. Michael Laposata, Chair of PNPL’s Diagnostic Medicine Focus Group, shared groundbreaking developments in integrated diagnostics and introduced the new John Sealy Diagnostic Center at UTMB-Galveston. We extend our thanks to all the attendees, speakers, and organizers of the event. If you missed it, stay tuned for upcoming insights and takeaways from the sessions! #ExecutiveWarCollege #EWC2024 #Pathology #HealthcareInnovation #PNPL
Panel of National Pathology Leaders’ Post
More Relevant Posts
-
Assistant Professor @ National Institute of Cardiovascular Diseases | Chemical Pathology, Medical Research | Innovator | Inquisitive | Nature enthusiast 🍀
I will be sharing some interesting insights regarding one and half years of our experience in external quality assessment at NICVD #Pathologyisvital #NationalPathologyWeek #RCPath
NICVD is celebrating 𝐍𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐖𝐞𝐞𝐤 𝟐𝟎𝟐𝟒 with a series of engaging activities. On 27th November, visit the pathology booth from 11:00 AM to 1:00 PM at the hospital lobby for quizzes, games, and educational sessions. On 28th November, join us from 10:00 AM to 12:00 PM in the Conference Hall for insightful discussions on pathology topics, including quality assessment in medical testing and the challenges of antimicrobial resistance. The event will close with case presentations, an overview of the Biofire FilmArray panel, prize distribution, and lunch. #NICVD #NationalPathologyWeek #PathologyWeek2024 #MedicalEducation
-
-
Last week, our Chief Scientific Officer, Steven de Maat, had the privilege of presenting TargED’s latest groundbreaking data at the International Symposium on Neuroprotection and Neurorepair (ISN&N) in Potsdam, Germany. Steven shared insights into our innovative approach to degrading blood clots in both microvascular and macrovascular thrombosis, showcasing how this breakthrough enables us to address and potentially cure many forms of thrombotic diseases. Our cutting-edge research holds significant promise in the treatment of acute ischemic stroke (AIS), where rapid clot degradation can minimize neurological damage and improve patient outcomes. Additionally, it opens new therapeutic possibilities for rare but severe conditions like thrombotic thrombocytopenic purpura (TTP), where targeted clot breakdown could help address the underlying pathology. We are incredibly proud of our team’s dedication to pushing the boundaries of science and making a meaningful impact in the field of neurorepair. A big thank you to ISN&N for hosting such an inspiring event and providing a platform for collaboration and exchange among global experts. Together, we’re shaping the future of healthcare. #Neuroprotection #Neurorepair #Innovation #Healthcare
-
-
NEW VJSessions 💬 🩸 In this exclusive session, leading experts Daniel Lenihan, Raúl Córdoba Mascuñano, and Iskra Pusic discuss the importance of #cardiooncology, awareness around the #ESC 2022 cardio-oncology guidelines, and the value of building a #multidisciplinary team 🔦 🫀 The experts share insights into the efforts of global societies to implement the ESC guidelines into #clinical practice, strategies to prevent #cardiactoxicities in patients being treated for #hematologicmalignancies, and the essential collaboration of #hematologists and #cardiologists Take a look 👉 https://lnkd.in/egvnPfsx #VJHemOnc
-
-
Advancing our Network Journey! New tools are building resilience, strengthening networks & helping teams support one another more effectively. Hear what Raja Noman Manzoor, Pathology Laboratory Director, Great Western Hospital, has to say about his network journey. Watch now to see how innovation is transforming #Pathology Learn more about the South 4 Pathology Partnership's collaborative approach to networking at https://lnkd.in/ebwajgT7 #PathologyWeek
-
#NationalPathologyWeek - Continuing our coverage, next up we’re spotlighting Janine Bontoft, Programme Director, Clinisys, who shares her journey in pathology and emphasises the crucial role it plays in healthcare. # Stay tuned as we bring you more expert insights throughout the week! #PathologyWeek #futureofpathology
-
NEW Interview 🎙️ Dr Joanna Wykrzykowska, Prof Holger Thiele and Prof Prof. Dr. Helge Möllmann discuss the findings and clinical implications of the PROVE Registry! https://ow.ly/GXPZ50SFQFy Watch now to uncover: 📊 Design and goal of the study ✅ Endpoints and results 📚 Implications on clinical practice #Cardiology #PROVE
-
-
Today at ADLM Middle East 2024, uncover how lab innovations are reshaping osteoporosis care with Dr. Rania Bedair, an expert in Chem ical Pathology and CMO of Life Diagnostics. Dive deep into the role of bone turnover markers (BTMs) in diagnosing, treating, and tracking osteoporosis progression. Discover key insights on bone remodeling and personalized treatment pathways that empower better patient outcomes and make fractures a thing of the past! Don't miss this opportunity to learn how labs hold the key to a healthier, fracture-free future. #ADLMME2024 #ADLMME #ADLMMiddlEast #OsteoporosisCare #LabInnovation #HealthcareTransformation
-
-
Take a look at the amazing paper by Hani Goodarzi et al. on orphan non-coding RNAs (oncRNAs) and their potential as cancer biomarkers.
Our Exai co-founder, Hani Goodarzi, in collaboration with Dr. Laura Essserman and Dr. Laura van ‘t Veer from UCSF, posted a preprint, which provides the origins and history of oncRNAs and their power to predict clinical outcomes and monitor disease burden based on the I-SPY 2 Trial. #ICYMI #https://lnkd.in/giVXVifV
-
🚨It's not too late to secure your free spot for TODAY'S #CardioOnc webinar at 14:00 BST | 09:00 EDT on 'IC-OS Journal Club: Post-hoc Analysis of a Large Clinical Trial Safety Database'👉🔗 https://ow.ly/7Ejt50TB6Yj Dr Rohan Bhandari, Dr Jose Alvarez-Cardona, Dr Dan Lenihan and Dr Joe Carver will discuss: 🔬The safety and tolerability profiles of Zanubrutinib and Ibrutinib in patients with B-cell malignancies 📊A post-hoc analysis of a large clinical trial safety database. #CardioOnc #Cardiology
-
-
Attending DDW? Let’s meet to learn about your clinical development plans.
Excited for #DDW24 in Washington? We sure are✨ ! Ready to explore groundbreaking GI research? Here's a sneak peek: • 2 oral presentations: Ulcerative Colitis week 16 results from the VERDICT trial & EoE digital pathology analysis algorithm • 6 posters highlighting results from GI research conducted by Alimentiv scientists • Featured Alimentiv speakers: Vipul Jairath | Niels Vande Casteele | Pavine Lefevre | Robert Battat | Dr. Virginia Solitano Come visit us at booth 2105. See you there! 👉 https://lnkd.in/gD3FjXuz #ClinicalTrials #DigestiveHealth #UlcerativeColitis #IBD #Alimentiv #ddw #ddw2024
-
